KA Imaging Announces New Funding for Its Activities

X-ray manufacturer KA Imaging announced today new funding for its activities. Both new investments focus on the Reveal™ 35C detector. In-Q-Tel, Inc. and INOVAIT are now part of the strong list of partners working with KA Imaging.

Spectral Imaging in the Emergency Department

One of the projects, “Single exposure Dual Energy Subtraction X-ray Device for Image Guided Therapy”, aims to use the Reveal 35C in the Emergency Room. KA Imaging, in partnership with Sunnybrook Research Institute, will obtain X-ray images from patients, and use it to develop new material separation imaging algorithms for real-time image-guided therapy applications.

Funding for this project was provided in part by INOVAIT through the Government of Canada’s Strategic Innovation Fund.

“We’re proposing a widely accessible and affordable solution to achieve improved soft tissue, bone and foreign object visibility, without added acquisition time or patient imaging dose,” explained Karim S. Karim, CTO of KA Imaging.

INOVAIT is a pan-Canadian network funded by the Government of Canada and hosted at the Sunnybrook Research Institute with the objective of building a truly integrated image-guided therapy ecosystem, fueling continuous innovation that revolutionizes healthcare globally. Through connecting, educating, and investing in the industry’s brightest minds and most promising ventures, INOVAIT will support and encourage collaborative development and the integration of artificial intelligence (AI) into medical technologies.

Accelerating innovation

KA Imaging has also signed a strategic investment and technology development agreement with In-Q-Tel, the not-for-profit strategic investor that accelerates the development and delivery of cutting-edge technologies to the U.S. intelligence and national security community and its allies.

“KA Imaging’s patented technology benefits application areas ranging from healthcare to non-destructive testing. Reveal’s unique energy subtraction capabilities and portability make it a solution that can be effectively and easily deployed in challenging environments,” said Michael Falcon, Investment Partner at In-Q-Tel.

“We are pleased to be part of the In-Q-Tel portfolio and look forward to expanding our relationship with IQT and its government partners”, said Amol Karnick, President and CEO of KA Imaging.

About Reveal 35C

Reveal™ 35C is a single exposure, portable, digital dual-energy subtraction (DES) X-ray detector. Powered by its exclusive SpectralDR™technology, it uses the same radiation dose as a traditional X-ray to create 3 different images without motion artifacts. In medical applications, this means a regular DR, plus a soft tissue and bone images. In the NDT market, Reveal’s energy subtraction capabilities can be translated into material differentiation, such as metals and plastics.

 

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”